title: Bucindolol (Bristol-Myers Squibb Co).
abstract: Bucindolol is a beta1 and beta2 adrenoceptor antagonist under development by Intercardia as a potential treatment for hypertension and congestive heart failure (CHF). Intercardia, Knoll AG and the NIH are conducting phase III trials for these indications. Intercardia is a subsidiary of Interneuron formed to acquire 80% of Cardiovascular Pharmacology and Engineering Consultants (CPEC) which includes the rights to bucindolol. CPEC was founded by researchers who had studied bucindolol in CHF for Bristol-Myers Squibb which ceased development of the compound in 1989 and licensed it to CPEC.
authors.affiliation: Istituto Chimica e Chimica Clinica, Catholic University, 00168 Rome, Italy. r.scatena@uniserv.ccr.rm.cnr.it
authors.forename: R
authors.initials: R
authors.lastname: Scatena